Arrhythmias & electrophysiology
Catheter ablation of paroxysmal atrial fibrillation and disease progression: Magnitude of the antiprogression effect and role of intervention timing
Pooled result · Progression to persistent AFResult — go to the resultRisk ratio 0.15 95% CI 0.08–0.28Authors' conclusion
The risk of progression to persistent AF at 3 years appears to be reduced by almost 7-fold in patients with paroxysmal AF treated using catheter ablation compared with patients treated using AAD therapy, regardless of the timing of the intervention.
Study context
- Population
- Patients with paroxysmal atrial fibrillation (AF)5 randomized controlled trials (RCTs)
- Comparison
- Catheter ablation vs AAD therapy
- Outcome
- Progression to persistent AF
- Follow-up
- 3 years
Pooled result
As reported in the abstract
Risk ratio
0.15
95% CI 0.08–0.28
P < 0.001
By group
Catheter ablationvs AAD
risk ratio 0.15 (95% CI 0.08–0.28); P < 0.001
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| Progression to persistent AF, by intervention timing (subgroup) · 3 yearsCatheter ablationvs AADFirst-line | 0.19 (0.07–0.48) | |
| Progression to persistent AF, by intervention timing (subgroup) · 3 yearsCatheter ablationvs AADNon-first-line | 0.13 (0.05–0.29) | |
| 0.050.21520Relative risk (log scale) |
- Progression to persistent AF, by intervention timing (subgroup): Pinteraction = .551
Progression to persistent AF, overall pooled rate · 3 years
- Pooled rate of progression to persistent AF
- 8.3% (95% CI 5.4-11.2, I2 = 67.2%)
Original publication
Catheter ablation of paroxysmal atrial fibrillation and disease progression: Magnitude of the antiprogression effect and role of intervention timing. Heart Rhythm. Published 19 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →